Adverse events in IBD: to stop or continue immune suppressant and biologic treatment. (March 2014)

• Record Type: Journal Article
• Authors: McLean, Leon P; Cross, Raymond K
• Is Part Of: Expert review of gastroenterology & hepatology. Volume 8:Number 3(2014)
• Page Start: 223
• Page End: 240
• Publication Date: 2014-03
• Subjects: adalimumab -- azathioprine -- certolizumab pegol -- Crohn's disease -- inflammatory bowel disease -- infliximab -- mercaptopurine -- methotrexate -- natalizumab -- ulcerative colitis; Gastroenterology -- Periodicals; Liver -- Diseases -- Periodicals; 616.3
• DOI: 10.1586/17474124.2014.881715
• Languages: English
• ISSNs: 1747-4124

Abstract

Abstract : Crohn's disease and ulcerative colitis affect an increasing number of patients. A variety of medical options exist for the treatment of these diseases including immune suppressants and biologic therapies. Unfortunately, these agents are associated with adverse events ranging from mild nuisance symptoms to potentially life-threatening complications including infections and malignancies. This review discusses adverse events associated with azathioprine, mercaptopurine, and methotrexate as well as anti-TNF-α and anti-integrin antibodies. In addition, adverse events associated with combination therapy are discussed as are clinical scenarios in which it may be reasonable to discontinue or de-escalate drug therapy. It is the responsibility of the treating gastroenterologist to effectively communicate the benefits and risks of therapy with patients; this review offers strategies that may assist providers in communicating risk with patients in addition to offering our perspective on whether modification or cessation of therapy can be considered.